@article{oai:air.repo.nii.ac.jp:00001543,
 author = {井上, 高光 and 佐藤, 一成 and 飯沼, 昌宏 and 土谷, 順彦 and 羽淵, 友則 and 加藤, 哲郎 and INOUE, Takamitsu and SATO, Kazunari and IINUMA, Masahiro and TSUCHIYA, Norihiko and HABUCHI, Tomonori and KATO, Tetsuro},
 issue = {1},
 journal = {秋田医学},
 month = {May},
 note = {This study was conducted to elucidate the clinical significance of the
alterations of HER-2 gene (HER-2) and chromosome 17 centromere in urine-exfoliated
cells by fluorescence in situ hybridization (FISH) in 103 patients with urothelial
transitional cell carcinoma. The additional increase of HER-2 (AI-HER2), gain of
chromosome 17 (G-17), and AI-HER2 with G-17 (AI-HER2+G-17) in the urine-exfoliated
cells were examined by FISH using DNA probes for HER-2 and chromosome
17 centromere. AI-HER2, AI-HER2+G-17, and G-17 were found in 13 (12.6%), 10
(9.7%), and 36 (35.0%) patients, respectively. The positive rate of the FISH (AIHER2,
AI-HER2+G-17, or G-17) was higher than that of cytology in total cases (57.3%
vs. 45.6%, P<0.001), in low-stage (pTa-I) tumors (44.3% vs. 27.9%, P= 0.003), and in
cases without CIS (42.0% vs. 31.9%, p<O.OOI). AI-HER2 was significantly more frequent
in tumors with two or more recurrences (25.9% vs. 7.9%, P=0.037). AI-HER2+
G-17 was more frequent in cases with primary CIS than without CIS (26.7% vs. 3.0%,
p =0.008). Numerical alterations of HER-2 and the chromosome 17 centromere in the
urine-exfoliated cells detected by FISH may reflect the malignant potential of urothelial
carcinoma and could be used as markers for the recurrence and the presence of primary
CIS.},
 pages = {63--69},
 title = {尿路上皮癌患者の尿中剥離細胞における17番染色体数およびHER-2遺伝子異常の臨床的意義},
 volume = {31},
 year = {2004}
}